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D4
ϩ as well as CD8 ϩ cells are considered important in antitumor responses (1) . Because tumor cells most often lack MHC class II and costimulatory molecules, CD4 ϩ T cell activation might require transfer of tumor-specific antigen (TSA) before presentation by professional antigen-presenting cells (APC).
There is indirect genetic and functional evidence for transfer and presentation of TSA by professional APC (2) (3) (4) . In one instance, priming of tumor APC could be directly demonstrated in a somewhat unphysiological model using a transfected pseudo-tumor antigen (ovalbumin), a cotransfected IL-3 gene, and a class-Irestricted T cell hybridoma as read-out (5) . Similarly, when carcinoma cells were cotransduced in vitro with granulocyte/macrophage colony-stimulating factor and CD40 ligand genes, dendritic cells (DC) that infiltrate tumors were shown to take up and present endogenous viral tumor-associated antigen in class-I-restricted fashion (6) .
There is as yet little evidence that TSA-specific T cells are activated in tumors. Tumor infiltrating T cells (TIL) possibly may have a tumor specificity because they display a limited TCR heterogeneity (7) . More convincingly, an increased frequency of melanoma-specific CD8 ϩ cells were found in metastatic lymph nodes (LN) (8) . However, there is no direct evidence for activation and proliferation of TSA-specific T cells in the tumor itself.
The BALB͞c MOPC315 myeloma secretes M315 monoclonal IgA with 2 315 L chains (9) (10) (11) . Because of their extreme diversity, each monoclonal Ig contains in its variable regions a unique TSA called idiotype (Id). Immunization with M315 induces an Id-specific resistance to a challenge with MOPC315 cells (12) . Subsequent work has demonstrated that an Id-peptide derived from the third hypervariable region (amino acids 91-101) of the 2 315 L chain, presented on the I-E d class II molecule, is recognized by Id-specific CD4 ϩ cells (13 APC. DC-like (APC-I) and macrophage (M⌽)-like (APC-II) cells were isolated essentially as described for spleen DC and M⌽, respectively (22) . Briefly, tissue fragments were digested with collagenase (400 units͞ml; Sigma) and DNase (0.33 mg͞ml; Sigma) for 45 min at 22°C. Released cells were pooled and washed, EDTA (pH 7.2) was added to 6 mM, and the cells were centrifuged over 54% Percoll (Amersham Pharmacia) at 1,500 ϫ g for 20 min at room temperature. The interphase cells (pellets contained the plasmacytoma cells) were cultured at 37°C. After 1.5-2 h, nonadherent cells were discarded. After an additional 12-18 h, detached cells (denoted APC-I) and remaining adherent (detached with 20 mM EDTA in PBS at 4°C for 15 min) cells (APC-II) were collected. APC I-and APC-II contained 1.3% and 0.8% of CD138 ϩ tumor cells, respectively. For T cellstimulation assays, APC were irradiated with 2,000 rads, a dose that inhibited growth of MOPC315 and J558 cell lines by 98% and 94%, respectively (data not shown). Flow Cytometry. Tumor tissue was treated with DNase and collagenase (as described above) and the released cells were used for staining. Unspecific stainings were blocked by incubation with heat-aggregated 30% normal rat serum in PBS for 10 min at 0°C. The following commercially available mAbs were used, conjugated with either FITC, phycoerythrin, allophycocyanin, or biotin: CD1d (1B1), CD4 (RM4.5), CD8 (53-6.7), CD11b (M1͞70), CD11c (HL3), CD13 (R3-242), CD19 (1D3), CD25 (3C7), CD40 (3͞23), CD69 (H1.2F3), CD80 (16-10A1), CD86 (GL-1), CD95 (Jo2), CD138 (281-2), CD154 (CD40Ligand; MR1), Ly-6G (Gr-1; RB6-8C5), DX-5 and various fluorochrome-conjugated, isotype-matched control mAbs (PharMingen). Purified M⌽-specific F4͞80 (C1:A3-1) and anti-scavenger receptor (2F8) mAbs were from ImmunoKontact (Bioggio, Switzerland). Human CTLA4Ig-IgG1 was a gift from P. Linsley (Immunex, Seattle). mAbs against the following specificities were affinity-purified and conjugated with FITC or biotin by using in-house procedures: TG-TCR-clonotype (GB113, ref. . Biotinylated Abs were detected with streptavidin (SA)-CyChrome (PharMingen), purified mAbs with phycoerythrin-labeled goat anti-rat-IgG Ig (Southern Biotechnology Associates). Combinations of the mAbs were used for double, triple, or quadruple stainings of cells. Triple stainings for CD4, CD8, and BrdUrd were carried out as described (27) . Cells were acquired and analyzed on a FACScalibur (Becton Dickinson) instrument with CELLQUEST software.
Immunofluorescence. Biopsies were embedded in OCT compound. Frozen sections were mounted on L-polylysine-coated glass slides, air-dried overnight, prefixed in acetone for 10 min, and then stored at Ϫ20°C. Single and double stainings of sections were done in several steps with avidin͞biotin blocking before each staining with unlabeled, FITC-conjugated or biotinylated mAbs against CD11b (M1͞70), CD31 (MEC 13.3), CD138 (281-2) (PharMingen), MHC class II (TIB120; 14.4.4S; ATCC), BrdUrd (Zymed BrdU Staining Kit), and TCR-TG clonotype (GB113). To detect unlabeled or FITC-conjugated mAbs, sections were incubated with biotinylated rabbit anti-rat IgG (Vector Laboratories) or biotinylated anti-FITC mAb (Sigma), respectively. For each mAb, a differently labeled reagent was used [SA-Texas Red (GIBCO), SA-Cy2, SA-Cy3 (Molecular Probes), or SA-peroxidase (ABC Vectastain kit, Vector)] to detect biotinylated Ab(s) from the previous step. For detection of BrdUrd, sections were fixed for 10 min in 4% paraformaldehyde. Nuclei were stained blue with 4,6-diamino-2-phenylindoldihydrochloride (DAPI) or hematoxylin. Pictures were made with a charge-coupled device camera (Hamamatsu, Ichinocho, Japan) and ADOBE PHOTOSHOP software.
Results
APC Purified from MOPC315 Tumors Spontaneously Present
Id. APC were isolated from large s.c. Id ϩ MOPC315 tumor tissue of BALB͞c mice, according to a procedure for isolation of DC and M⌽ from the spleen. APC I and APC II, anticipated to be enriched for DC and M⌽, respectively, were irradiated to inhibit proliferation of any contaminating tumor cells (1.3%) and tested for their ability to activate various types of Id-specific CD4 ϩ T cells in the absence of added antigen (Fig. 1) . Activation was measured both as proliferation and lymphokine production (IL-2 for naive cells, IFN-␥ for Th1, IL-4 for Th2), and results were always concordant (data not shown).
Both types of tumor APC could spontaneously stimulate T cells from TCR-TG mice (Fig. 1 A) . T cell responses were weaker than those obtained by adding an optimal concentration of synthetic Id-peptide to cultures. The responses were transgene specific because T cells from N-TG mice did not react. Responses were Id specific because APC isolated from an Idnegative tumor (J558) failed to elicit any response, although they could present synthetic Id-peptide. APC from the tumor were more efficiently primed than spleen APC, which were nonstimulatory.
APC I and APC II isolated from MOPC315 tumors of TCR-TG mice gave similar results demonstrating that Id-specific T cells do not extinguish Id-primed APC (Fig. 1B) . APC isolated from large MOPC315 tumors (Ͼ1.5 cm, serum M315 Ͼ140 g͞ml) stimulated T cells to a greater extent than their counterparts from intermediate-size (0.5-1.5 cm; serum M315 50-140 g͞ml) tumors (Fig. 1B) . [Serum M315 correlate with tumor size (weight, diameter); ref. 28 .] Responses could clearly be detected with 2,500 APC per well (Fig. 2) , corresponding to 250-625 class II ϩ CD80͞86 ϩ cells (see later). Many Id-specific TCR-TG LN cells additionally express an endogenous ␣-chain, and thus an unknown second reactivity (29) . To exclude this confounding factor, we compared the ability of Id-primed APC to stimulate naive CD4 ϩ cells and Th2-polarized cells, both obtained from recombination-deficient TCR-TG SCID mice of barrier-bred, specific pathogen-free standard. APC-I cells stimulated proliferation of naive CD4 ϩ cells, although to a lesser extent than Th1- (Fig. 1B) or Th2-polarized cells (Fig. 2) . Responses of Id-specific naive CD4 ϩ T cell were blocked by two different anti-class II mAbs and by a human CTLA4Ig hybrid molecule that binds to mouse CD80 and CD86 (data not shown).
MOPC315 Cells Isolated from s.c. Tumors Do Not Themselves Stimulate
Class II-Restricted, Id-Specific T Cells. Freshly isolated ex vivo MOPC315 cells, identified by their expression of a plasma cell marker CD138 (Syndecan-1), did not express class II molecules as detected by immunohistochemistry (Fig. 3A) or flow cytometry (data not shown). Because either transient or physically undetectable levels of class II expression might have functional consequences, it was important to test Id-presentation capability of MOPC315 in functional T cell assays. First, APC function of pellet cells from the 54% Percoll gradient, containing about 70% MOPC315 cells, was compared with that of APC-I and -II preparations (1.3% MOPC315 cells). The results strongly argue against MOPC315 cells themselves being able to present Id (Fig. 4A) .
Secondly, APC from MOPC315 tumors established in Rag2 (Fig. 3B, arrows) . The CD11b ϩ APC were located beneath CD31 ϩ endothelial cells of tumor vessels (Fig. 3C) . The frequency of APC was 5-7% in minute (1-2 mm) tumors, but dropped rapidly with increase of the tumor size, which indicates that tumor cells outgrow APC as tumor enlarges (Fig. 5B) . TCR-TG mice were injected with high loads of MOPC315 cells to partially overcome their tumor protection (28) and analyzed when MOPC315 tumors were still small (Ͻ0.5 g, serum M315 Ͻ 50 g͞ml), before deletion of Id-specific CD4 ϩ cells (28) . TIL were strongly skewed toward CD4 ϩ in MOPC315 tumors (Fig. 6 ), compared with lymphoid organs in TCR-TG mice (14) . Moreover, Id-specific CD4 ϩ TIL were much more frequent in Id ϩ MOPC315 than in Id Ϫ J558 tumors (Figs. 3 D and E and 6), and often occurred as blasts in clusters (Fig. 3D ).
Id-Specific CD4
CD4 ؉ Blasts in Id ؉ Tumors Are Id Specific and Proliferate. As analyzed by flow cytometry, CD4 ϩ blasts in MOPC315 tumors were enriched for Id-specific CD4 ϩ cells, whereas small CD4 ϩ cells were mainly of the nonspecific type (Fig. 7) . These results are consistent with the finding of many GB113 ϩ blasts in sections of small MOPC315 tumors (Fig. 3 D and F) . The sparse CD8 ϩ cells in MOPC315 tumors (Fig. 6A) were all of a small size (data not shown).
To investigate in vivo proliferation of Id ϩ -specific CD4 ϩ cells, TCR-TG mice with small MOPC315 tumors were given BrdUrd for the last 3 days before analysis. Id-specific T cells, analyzed in sections, had incorporated BrdUrd, and thus had proliferated (Fig. 3G) . As quantified by flow cytometry, a considerable fraction of Id-specific CD4 ϩ cells were BrdUrd ϩ , whereas incorporation into nonspecific CD4 ϩ cells was negligible (Fig.  8A) . Id-specific CD4 ϩ cells incorporated BrdUrd even in larger MOPC315 tumors (Ͼ0.5 g, serum M315 Ͼ 50 g͞ml) (Fig. 8A) , suggesting that they proliferate until they become deleted (data not shown, and ref. 28) . BrdUrd incorporation in Id-specific CD4 ϩ cells was much more frequent in MOPC315 tumors than in J558 tumors, demonstrating the Id specificity of the proliferation (Fig. 8B) . 
Id-specific CD4
ϩ cells in small MOPC315 tumors displayed an activated phenotype with elevated surface expression of CD69 and CD25 (Fig. 7B) . Activation was Id specific, both at the T cell (Id specific vs. nonspecific) and tumor cell (Id ϩ vs. Id (Fig. 3H) . Moreover, Id-specific T cells (Fig. 3I ) and the APC (Fig. 3C) were close to CD31 (PECAM-1) ϩ tumor vessels. This proximity suggests that Id-specific T cells are interacting with the Id-primed APC in the tumor.
Discussion
In this study, we show that TSA (Id)-specific CD4 ϩ T cells in TCR-TG mice are activated and proliferate in small extramedullary Id ϩ plasmacytomas: (i) The CD4 ϩ ͞CD8 ϩ ratio was skewed toward CD4 in tumor tissue; (ii) CD4 ϩ blasts within (30) . Importantly, the APC and Id-specific T cells coclustered beneath endothelium of CD31 ϩ tumor microvessels. These data suggest that angiogenesis and diapedesis of APC in tumor may be related phenomena. It has been suggested that monocytes that traverse the endothelium by reverse transmigration differentiate into veiled DC (31) .
APC could become primed in situ by endocytosis of myeloma protein in the extracellular tumor fluid, e.g., by means of Fc receptors. In fact, Id priming of APC may depend on secretion of Ig by tumor cells, as suggested by experiments in which TG mice were protected against an A20 B lymphoma transfectant that secretes 2
315
, but succumb to another A20 transfectant that does not secrete 2 315 (16). Experiments with nonsecretory hemagglutinin A20 transfectants may be similarly interpreted (32) . These studies point to a significance of secretion of TSA, which probably reflects the need for uptake and processing by costimulation-competent class II We and others (16) (17) (18) (19) 21) have reported that Id-specific CD4 ϩ cells have an antimyeloma effect. However, although Id-specific CD4 ϩ cells can protect against challenges with small numbers of MOPC315 cells (14, 16) , Id-specific CD4 ϩ cells eventually become deleted within progressive plasmacytomas established by injection of high loads of tumor cells (28) . The present results demonstrate that a phase of CD4 ϩ T cell activation and proliferation within the tumor precedes the deletion. A similar activation and proliferation of Id-specific CD4 ϩ T cells probably takes place when the MOPC315 challenge is success- fully fought off (14, 16) . The molecular mechanism by which activated CD4 ϩ cells can eliminate MOPC315 cells is unknown.
It has been suggested that immunization with TSA-pulsed DC in patients with established disease may be beneficial (35) . However, if TSA-primed host DC are already present in the tumor (present results), does it make sense to vaccinate with TSA-primed DC? Probably so, for a number of reasons. First, in a number of tumor diseases, host DC may in fact not be spontaneously TSA-primed, possibly because of lack of TSA transfer (16, 33, 34) . Second, even though host DC might be primed with TSA, they could, in many tumors, fail to adequately stimulate T cells. For example, tumors could inhibit terminal maturation of DC. Third, DC incubated with TSA in vitro may have better loaded MHC molecules, and, therefore, a higher stimulatory potential, than spontaneously TSA-primed tumor DC. Activated Id-specific CD4 ϩ cells become deleted with progressive myeloma disease in mice (28, 36) . Therefore, Id vaccination of multiple myeloma patients is probably best performed after high-dose chemotherapy and stem-cell transplantation at a time when tumor burden is very low and new (Id-specific) T cells are being educated in the thymus. Likewise for other tumor types, it might be important to minimize the tumor load prior to DC vaccination immunotherapy.
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